SCHEMBL9025634

SCHEMBL9025634

O=C1COc2ccccc2CN1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.59
AKR1C3 P42330 1/20 0.59
AKR1C2 P52895 1/20 0.59
AKR1C1 Q04828 1/20 0.59
OXTR P30559 1/20 0.52
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
DAPK3 O43293 1/20 0.37
RET P07949 1/20 0.37
PRKACA P17612 1/20 0.37
GRK5 P34947 1/20 0.37
CDK8 P49336 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
CDK5 Q00535 1/20 0.37
PRKCQ Q04759 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9870509 0.82 ALDH1A1 (0.45) ALDH1A1AKR1C3AKR1C2AKR1C1OXTR
SCHEMBL23142218 0.77 ALDH1A1 (0.46) ALDH1A1AKR1C3AKR1C2AKR1C1PARP1
SCHEMBL28913426 0.77 ALDH1A1 (0.46) ALDH1A1AKR1C3AKR1C2AKR1C1GAA
SCHEMBL14084321 0.76 GAA (0.63) ALDH1A1AKR1C3AKR1C2AKR1C1OXTR
SCHEMBL30094694 0.74 ITGB2 (0.48) ALDH1A1AKR1C3AKR1C2AKR1C1GAA
SCHEMBL1950586 0.74 ALDH1A1 (0.43) ALDH1A1AKR1C3AKR1C2AKR1C1CA12
SCHEMBL11195016 0.73 GAA (0.60) ALDH1A1AKR1C3AKR1C2AKR1C1OXTR
SCHEMBL147262 0.73 GAA (0.60) ALDH1A1AKR1C3AKR1C2AKR1C1OXTR
SCHEMBL31020334 0.73 ALDH1A1 (0.52) ALDH1A1AKR1C3AKR1C2AKR1C1GAA
SCHEMBL5045846 0.72 MAOA (0.50) ALDH1A1AKR1C3AKR1C2AKR1C1OXTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022057142-A1 STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF 广州中医药大学(广州中医药研究院) 2022-03-24 WO claimed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
WO-2023280296-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2023-01-12 WO disclosed
WO-2022057142-A1 STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF 广州中医药大学(广州中医药研究院) 2022-03-24 WO disclosed
WO-2016124139-A1 HETEROCYCLIC-SUBSTITUTED N-SULFONYLBENZAMIDE DERIVATIVES, PREPARATION METHOD FOR DERIVATIVES, AND PHARMACEUTICAL USE OF DERIVATIVES 上海海雁医药科技有限公司 2016-08-11 WO disclosed
EP-2742039-B1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2015-09-16 EP disclosed
EP-2742039-B1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN LA ROCHE (CH) 2015-09-16 EP disclosed
US-8871756-B2 Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease HOFFMANN-LA ROCHE INC. (US) 2014-10-28 US disclosed
EP-2742039-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. Hoffmann-La Roche AG (CH) 2014-06-18 EP disclosed
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN-LA ROCHE INC. 2013-08-01 US disclosed
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN-LA ROCHE INC. 2013-08-01 US disclosed
WO-2013020993-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-14 WO disclosed
WO-2013020993-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-14 WO disclosed
EP-0463810-B1 Heterocyclic compound and psychopharmaceutical composition containing same SUNTORY LTD (JP) 1996-01-10 EP disclosed
EP-0376633-B1 Benzoxazepine derivatives SUNTORY LTD (JP) 1994-10-12 EP disclosed
US-5158947-A CONDENSED HETEROCYCLIC COMPOUNDS AND PSYCHOPHARMACEUTICAL COMPOSITION CONTAINING SAME SUNTORY LIMITED (JP) 1992-10-27 US disclosed
EP-0463810-A1 Heterocyclic compound and psychopharmaceutical composition containing same SUNTORY LIMITED (JP) 1992-01-02 EP disclosed
EP-0376633-A2 Benzoxazepine derivatives SUNTORY LIMITED (JP) 1990-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE CFTR, H1-10, RECQL ALDH1A1 2189/4885AKR1C3 3855/4885AKR1C2 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.